Nobel Biocare CEO under pressure over dispute with Swedish authorities - report

ZURICH (Thomson Financial) - Nobel Biocare AB chief executive Heliane Canepa has come under fire over allegations that the Swedish-Swiss dental implant maker has issued misleading statements regarding the safety of its NobelDirect and NobelPerfect implants, Swiss Sunday paper SonntagsZeitung reported.

The two implants have been linked with cases of bone loss in the past.

Both the Swedish stock market watchdog, as well as Sweden's Medical Product Agency (SMPA), allege that the company has deliberately misinterpreted SMPA statements and misinformed the public over the safety of its products, the newspaper said, citing information from Sweden.

The newspaper also claims that Canepa has lost the confidence of board president Rolf Soiron.

Shares of the dental implant maker came under pressure on Friday amid speculation that former Syngenta AG (nyse: SYT - news - people ) CFO Domenico Scala could replace Canepa at the helm of the company.

Comments